Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 15/20 | 0.89 |
| ▸ | ROCK2 | O75116 | 17/20 | 0.74 |
| ▸ | CLK2 | P49760 | 1/20 | 0.61 |
| ▸ | BLK | P51451 | 1/20 | 0.61 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.61 |
| ▸ | STK3 | Q13188 | 1/20 | 0.61 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.61 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.61 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.61 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18056386 | 0.94 | ROCK1 (1.00) | ROCK1ROCK2CLK2BLKCSNK2A1 | |
| Trifluoroacetic Acid SCHEMBL18038261 | 0.86 | ROCK1 (0.71) | ROCK1ROCK2 | |
| SCHEMBL18038217 | 0.85 | ROCK1 (1.00) | ROCK1ROCK2 | |
| SCHEMBL18038381 | 0.85 | ROCK1 (0.81) | ROCK1ROCK2CLK2BLKCSNK2A1 | |
| Belumosudil SCHEMBL878258 | 0.81 | ROCK2 (0.91) | ROCK1ROCK2CLK2BLKCSNK2A1 | |
| Trifluoroacetic Acid SCHEMBL18038237 | 0.81 | ROCK2 (0.68) | ROCK1ROCK2 | |
| SCHEMBL17040955 | 0.79 | ROCK2 (0.78) | ROCK1ROCK2CLK2BLKCSNK2A1 | |
| Trifluoroacetic Acid SCHEMBL18038203 | 0.79 | ROCK2 (0.85) | ROCK1ROCK2 | |
| SCHEMBL24933400 | 0.79 | ROCK2 (0.75) | ROCK1ROCK2CLK2BLKCSNK2A1 | |
| Trifluoroacetic Acid SCHEMBL18038151 | 0.79 | ROCK1 (0.72) | ROCK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10112935-B2 | Indazolyl thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease | LYCERA CORPORATION (US) | 2018-10-30 | — | — | US | disclosed |
| US-20180093978-A1 | INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-04-05 | — | — | US | disclosed |
| EP-3262041-A1 | INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | Lycera Corporation (US) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016138335-A1 | INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | LYCERA CORPORATION (US) | 2016-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112935-B2 | Indazolyl thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease | ROCK1, ROCK2, CIT | ROCK1 1/4885ROCK2 2/4885CLK2 679/4885 |
| US-20180093978-A1 | INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | ROCK1, ROCK2, CIT | ROCK1 1/4885ROCK2 2/4885CLK2 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.